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Abstract
Background: Dyslipidaemia is an important but modifiable risk factor of cardiovascular disease (CVD) in type 2
diabetes. Yet, the effectiveness of lipid regulating drugs in Asians is lacking. We examined the effects of lipid
control and treatment with lipid regulating drugs on new onset of CVD in Chinese type 2 diabetic patients.
Methods: In this prospective cohort consisting of 4521 type 2 diabetic patients without history of CVD and naïve
for lipid regulating treatment recruited consecutively from 1996 to 2005, 371 developed CVD after a median
follow-up of 4.9 years. We used Cox proportional hazard regression to obtain the hazard ratios (HR) of lipids and
use of lipid regulating drugs for risk of CVD.
Results: The multivariate-adjusted HR (95% confidence interval) of CVD in patients with high LDL-cholesterol (≥ 3.0
mmol/L) was 1.36 (1.08 - 1.71), compared with lower values. Using the whole range value of HDL-cholesterol, the
risk of CVD was reduced by 41% with every 1 mmol/L increase in HDL-cholesterol. Plasma triglyceride did not
predict CVD. Statins use was associated with lower CVD risk [HR = 0.66 (0.50 - 0.88)]. In sub-cohort analysis, statins
use was associated with a HR of 0.60 (0.44 - 0.82) in patients with high LDL-cholesterol (≥ 3.0 mmol/L) and 0.49
(0.28 - 0.88) in patients with low HDL-cholesterol. In patients with LDL-cholesterol < 3.0 mmol/L, use of fibrate was
associated with HR of 0.34 (0.12 - 1.00). Only statins were effective in reducing incident CVD in patients with
metabolic syndrome [(HR = 0.58(0.42–0.80)].
Conclusions: In Chinese type 2 diabetic patients, high LDL-cholesterol and low HDL-cholesterol predicted incident
CVD. Overall, patients treated with statins had 40-50% risk reduction in CVD compared to non-users.
Background
In this global epidemic of type 2 diabetes, Asia will have
the highest prevalence with a disproportionate disease
burden in young to middle aged adults [1]. Cardiovascu-
lar disease (CVD) is a leading cause of morbidity and
mortality in diabetes patients resulting in poor quality of
life and loss of societal productivity [2]. Controlling
blood pressure, blood glucose and blood lipids reduce
CVD risk in type 2 diabetic patients, including Chinese
[3].
However, to date, most of the randomized clinical
trials and meta-analyses were conducted in Caucasian
populations with scarcity of data in Asians. In addition,
a major chasm between guidelines and practice exists in
developing countries, leading to delayed treatment of
risk factors and preventable complications. For example,
in a multinational survey involving more than 9000 type
2 diabetic patients in developing regions, 35% of patients
not treated with lipid regulating drug had low-density
lipoprotein cholesterol (LDL-C) ≥ 2.6 mmol/L [4]. In
areas such as Hong Kong where health care system is
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lipid-regulating drug to a diabetic patient in public clini-
cal setting is often restricted for secondary prevention of
CVD. In light of the clinical inertia, there is a need to
seek evidence in Asian diabetic patients to motivate
physicians to prescribe these drugs and support their
use in patients without history of CVD.
In this analysis of 4521 type 2 diabetic patients, we
examined the clinical utility of internationally recom-
mended treatment targets for lipids and effectiveness of
lipid regulating drugs in preventing incident CVD in
Chinese type 2 diabetic patients. We also identified
high-risk patients in whom the lipid regulating drugs
were particularly effective.
Methods
The Hong Kong Diabetes Registry was established in
1995 at the Prince of Wales Hospital as part of a quality
improvement program. This comprehensive registry has
enabled us to examine the epidemiology and impact of
treatments on clinical outcomes in real practice in Chi-
nese diabetic patients. Hong Kong is a cosmopolitan city
with 7 million people, the majority of whom are of
southern Chinese ethnicity. The Prince of Wales Hospi-
tal is the teaching hospital of the Chinese University of
Hong Kong and serves more than 1.2 million people in
her catchment area. Since 1995 and on a weekly basis,
we examined 30 - 50 diabetic patients referred from
community-based primary care and hospital-based spe-
cialist clinics in an ambulatory setting. The 4-hour com-
prehensive assessment was performed according to a
protocol modified from the European DiabCare protocol
[5]. Once patients underwent the assessment, their out-
comes and clinical data are monitored until time of
d e a t h .W r i t t e ni n f o r m e dc o n s e n tw a so b t a i n e df r o ma l l
patients for research and publication purpose.
Between 1996 and 2005, 7387 diabetic patients were
consecutively recruited in the Hong Kong Diabetes Reg-
istry. We excluded 2866 patients from this study due to
having history of CVD at baseline (n = 1166), use of
lipid-regulating drug at or before enrolment (n = 907),
missing data for any variables included in the analysis (n
= 522), having non-type 2 diabetes (n = 271). As a
result, 4521 patients with type 2 diabetes without prior
history of CVD and naïve to lipid-regulating drugs were
included in the analysis.
All-cause death on or before July 2005 was recorded
or otherwise censored on 30
th July 2005. We retrieved
all discharge diagnoses, causes of death and drug dis-
pensing data using the Hospital Authority Central Com-
puter System which was used by all public hospitals in
Hong Kong. A cardiovascular event was defined as cor-
onary heart disease and/or stroke according to the Inter-
national Classification of Disease, Ninth Revision [3].
Coronary heart disease was defined as the first incidence
of acute myocardial infarction (code 410) and coronary
death (codes 410, 411-414, and 428), nonfatal ischemic
heart disease (codes 411-414), nonfatal heart failure
(code 428), and coronary revascularization (procedure
code 36) and percutaneous transluminal coronary angio-
plasty or coronary atherectomy (procedure code 00.66).
Stroke was defined as first incidence of stroke (codes
430 - 434 and 436) or death from stroke (codes 430 -
438) [3]. The above data was matched by the Hong
Kong identity card number, which is a unique identifica-
tion number issued by the government for all the Hong
Kong residents.
Clinical and laboratory measurement
The assessment methods, definitions and laboratory
assays have been described [3]. In brief, patients
attended the centre after an overnight fast of at least
eight hours for clinical measurements and laboratory
tests. Full lipid profile consisting of total cholesterol, tri-
glycerides and high-density lipoprotein cholesterol
(HDL-C) was measured by enzymatic methods on a
Hitachi 911 automated analyzer (Boehringer Mannheim,
Mannheim, Germany) using reagent kits supplied by the
manufacturer. The low-density lipoprotein cholesterol
(LDL-C) was calculated using the Friedewald equation.
All laboratory measurements were conducted by the
Department of Chemical Pathology of the Prince of
Wales Hospital, which was accredited by the Australian
Quality Assurance Program.
Statistical analysis
The SAS (release 9.10; SAS Institute, Cary, NC) pro-
gram was used for all analysis. Follow-up time in years
was estimated from enrolment to the earliest date of a
CVD event, death or censoring whichever came first.
We used yes/no coding for use of statins, fibrates and
other drugs during the follow-up period. Cox propor-
tional hazard regression was used to obtain hazard ratio
(HR) with 95% confidence intervals (95% CI) of lipids
(LDL-C, HDL-C, triglyceride) and lipid regulating drugs
(i.e. statins and fibrates) for risk of CVD.
Firstly, the linearity of lipids for CVD risk was exam-
ined using restricted cubic spline Cox model analysis
[6]. Restricted cubic spline consists of piecewise cubic
polynomials that are connected across different intervals
of a continuous variable. It can fit sharply curving
shapes [6]. As in our previous analyses [7,8], we chose 4
knots at quartiles 0.05, 0.35, 0.65 and 0.95 which were
suggested to offer adequate fit of the model with good
compromise between flexibility and loss of precision due
to overfitting of a small sample [6]. Initially, spline terms
of LDL-C, HDL-C and triglyceride were entered the
spline Cox model. We then performed a forward
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removal to identify possible confounding factors includ-
ing clinical and biochemical covariates at enrolment,
drug use during follow-up period (See table 1 for a list
of candidate covariates) and years of enrolment. Based
on the HR curves of lipids, we identified threshold value
for CVD risk and categorized patients using these cutoff
values. Otherwise, we treated the covariates as linearly
associated with CVD. We performed Cox model analysis
to obtain the HR of lipids for CVD with adjustments for
other lipid parameters and covariates.
We then examined the HRs of use of statins and
fibrates for CVD defined as drug use from enrolment to
the first CVD event, death or censoring date whichever
came first. We used logistic regression procedures and a
stepwise algorithm with P = 0.30 for entry and stay to
select baseline covariates including age, sex, year of
enrolment, waist circumference, LDL-C, HDL-C, trigly-
ceride, smoking status, body mass index, HbA1c, systolic
blood pressure, Ln [(urine albumin-creatinine ratio
(ACR)) + 1], estimated glomerular filtration rate (eGFR),
duration of disease, retinopathy and neuropathy to esti-
mate propensity scores for adjustment of probabilities of
use of statins and fibrates [9]. Age, waist circumference,
LDL-C, HDL-C, triglyceride, HbA1c,L n ( A C R+1 ) ,
eGFR, duration of disease, retinopathy and neuropathy
were selected for the propensity score for statins (c-sta-
t i s t i c=0 . 7 9 ) .A g e ,L D L - C ,H D L - C ,t r i g l y c e r i d e ,H b A 1c,
Table 1 Baseline clinical and biochemical characteristics of Chinese type 2 diabetic patients with no history of
cardiovascular disease (CVD) divided according to the development of CVD during 4.9 (2.8-7.0) years of follow-up
Non-CVD (n = 4150) CVD (n = 371)
median or% IQR* median or% IQR* P value
Age (years) 54 21 64 16 <.0001‡
Male Gender 45.7% (1898) 52.8% (196) .0086
Smoking status <.0001†
Ex smoker 13.3% (553) 20.2% (75)
Current smoker 14.9% (620) 21.2% (78)
Waist circumference (men, cm) 87.5 12.5 88.0 11.0 .2384
Waist circumference (women, cm) 82.5 13.0 84.5 13.0 .0165
Body mass index (kg/m
2) 24.6 5.0 24.9 4.3 .4409
Duration of diabetes (Years) 5 9 9 10 <.0001‡
Systolic blood pressure (mmHg) 132 25 141 25 <.0001‡
Diastolic blood pressure (mmHg) 75 14 75 13 .1313‡
HbA1c (%) 7.2 2.1 7.7 2.6 <.0001‡
Spot urine albumin creatinine ratio (mg/mmol) 1.55 5.75 7.13 54.8 <.0001‡
eGFR (ml min
-1 1.73 m
-2) ξ 109 39 93 41 <.0001‡
LDL-C (mmol/L) 3.1 1.2 3.4 1.3 <.0001‡
≥3.0 mmol/L 56.1%(2330) 69.0%(256) <.0001†
HDL-C (mmol/L) 1.28 0.45 1.18 0.45 <.0001‡
HDL-C <1.0 in male or 1.3 in female 23.8%(987) 25.9%(96) .3655†
Triglyceride (mmol/L) 1.27 0.97 1.40 1.01 .0031‡
Drug use at enrolment
Use of antihypertensive drugs at enrolment 29.7%(1231) 42.3%(157) <.0001†
Drug use during follow-up
Use of statins during follow-up 22.7%(942) 22.6%(84) .9799†
Use of fibrates during follow-up 6.41%(266) 4.58%(17) .1639†
Use of other lipid lowering drugs during follow-up 0.29% (12) 0.27% (1) .3832 ††
Use of RAS inhibitors during follow-up 48.9% (2029) 62.5% (232) <.0001†
Use of gliclazide during follow-up 43.7% (1814) 37.2% (138) .0152†
Use of rosiglitazone during follow-up 4.9% (204) 1.6% (6) .0038†
Use of other oral antidiabetic drugs during follow-up 79.0% (3280) 80.3% (298) .5587†
Use of insulin during follow-up 32.4%(1345) 45.0%(167) <.0001†
Events during follow-up
Death during follow-up 5.42% (225) 27.5%(102) <.0001†
*, Median (IQR = interquartile range); †, derived from Chi-square test; ††, Derived from Fisher’s exact test; ‡, derived from Wilcoxon two-sample test; ξ, eGFR =
glomerular filtration rate from modified MDRD formula; ¶, including drug use at enrolment except for statins and fibrates (users at enrolment were excluded)
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and neuropathy were selected to predict use of fibrates
during follow-up period (c-statistics = 0.79). Stratified
models on deciles of both propensity scores were used
to adjust for likelihood to use statins and fibrates during
follow-up period. We further adjusted for covariates
identified in the initial restricted cubic spline models to
analyse the effects of statins and fibrates on CVD.
Correlations between pairs of baseline covariates were
checked using Pearson’s correlation test and none of the
pairs were highly correlated (correlation coefficient <
0.60). Proportional hazards were checked as before. A
two-sided P value < .05 was considered to be significant.
Results
Baseline characteristics
During a median follow up period of 4.9 years (interquar-
tile range 2.8 - 7.0 years), 371 (8.2%) of 4521 subjects
developed CVD. Patients who had new onset of CVD
were older, more likely to be men and smokers, had longer
disease duration, higher LDL-C, triglyceride, HbA1c, ACR,
lower HDL-C and eGFR than those without. These
patients were also more likely to receive insulin and less
likely to receive rosiglitazone and gliclazide (Table 1). In
the whole cohort, only 23% and 6% of patients were pre-
scribed statins or fibrates respectively during follow-up.
Lipid profile and risk for CVD
In the entire cohort and before adjustment, CVD risk
was positively associated with LDL-C and triglyceride
but negatively with HDL-C (figure 1, black line). After
adjustment for age, smoking status, duration of diabetes,
HbA1c, Ln (ACR + 1), use of gliclazide or rosiglitazone
during follow-up, years of enrolment (selected by the
stepwise algorithm with P = 0.10 for entry and stay); the
HR of CVD increased sharply when LDL-C was ≥ 3.0
mmol/L (Figure 1, blue line). The CVD risk declined
linearly with increasing HDL-C with no definite thresh-
old (Figure 2, blue line). The HR of CVD with triglycer-
ide became insignificant after adjusting for confounders
(Figure 3, blue line).
Using LDL ≥ 3.0 mmol/L as the cutoff point, the HR
for CVD risk was 1.41 (1.13 - 1.75, p = 0.0024) as com-
pared to those with LDL < 3.0 mmol/L. After adjusting
for covariates, the HR was attenuated to 1.36 (1.08 -
1.71, p = 0.0095). Using the whole range of HDL-C
values, with every 1 mmol/L increase, the HR for CVD
was 0.61 (0.45 - 0.84, p = 0.0080), which decreased to
0.59 (0.42 - 0.82, p = 0.0020) after adjustment for cov-
ariates (Table 2).
Use of lipid lowering drugs and risk for CVD
In this new-user cohort, use of statins reduced CVD risk
by 34% after controlling for baseline covariates and use
of other medications during follow-up. Use of fibrates
did not reduce CVD risk after adjustment for other cov-
ariates (Table 3). The trend of risk reduction was con-
sistent in nearly all subgroups stratified by LDL-C and
HDL-C levels, reaching significance for some subgroups.
In patients with LDL-C ≥ 3 mmol/L, statins significantly
reduced CVD risk by 40%. In patients with LDL-C < 3
m m o l / L ,f i b r a t e sr e d u c e dC V Dr i s kb y6 6 % .I np a t i e n t s
with low HDL-C (< 1.0 mmol/L in men and < 1.3
mmol/L in women) and those with concomitant meta-
bolic syndrome [10], statins reduced CVD risk by 51%
and 42% respectively.
Discussion
Our study results revealed high LDL-C and low HDL-C,
but not triglyceride, predicted incident CVD in Chinese
type 2 diabetic patients. Using spline analysis, the opti-
mal LDL-C level for CVD risk was <3 mmol/L while
HDL-C exhibited a continuous and linear relationship
with CVD risk. Use of statins was associated with 34%
risk reduction in CVD while the risk reducing effect of
fibrates was rendered insignificant after adjusting for
confounders. On subgroup analysis, statins use reduced
CVD risk by 40% in patients with LDL-C≧3.0 mmol/L
and by 51% in those with low HDL-C (<1.0 mmol/L in
male and <1.3 mmol/L in female) and 42% in those with
metabolic syndrome. In patients with LDL-C<3 mmol/L,
fibrates use was associated with 66% risk reduction of
CVD with borderline significance.
Lipid profile, use of lipid regulating drugs and CVD risk
Epidemiological studies and interventional trials con-
firmed the predictive value of high LDL-C on risk of
CVD. These risks were accentuated by 2-3 folds in
type 2 diabetic patients for the same number of risk
factors [11,12]. Furthermore, type 2 diabetic patients
are often insulin resistant with a typical dyslipidaemic
pattern of low HDL-C and high triglyceride [13-15].
Despite the similar LDL-C levels between type 2 dia-
betic and non-diabetic subjects, the high triglyceride
contributes to increased concentration of small dense
LDL-C particles which are more atherogenic. Type 2
diabetic patients are also more likely to have oxidized
and glycated LDL-C which are readily taken up by
macrophages to form atheromatous plaques. Given the
consistency of interventional data, lowering of LDL-C
using HMGcoA reductase inhibitors (statins) remains
the primary target in preventing CVD in type 2 dia-
betes [2,16,17].
As early as in 1977, the Framingham study demon-
strated an inverse association between HDL-C and inci-
dence of coronary heart disease after adjustment for
other lipid parameters and risk factors [18]. In the Asia
Pacific Cohort Studies Collaboration consisting of more
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were independent risk factors for coronary heart disease
in Asians [19]. By contrast, the prognostic significance
of triglyceride in CVD remains controversial [19-23].
While some researchers have reported triglyceride to be
the most predictive lipid parameter for CVD, in a recent
meta-analysis by the Emerging Risk Factors Collabora-
tion, such risk association was not confirmed after con-
trolling for other confounders [23]. In this analysis,
triglyceride also did not predict incident CVD in our
Chinese type 2 diabetic patients after adjusting for
confounders.
Figure 1 Hazard ratio of LDL-C for risk of CVD using restricted cubic spline Cox model analysis. Dotted curve (black), not adjusted for other
covariates except for HDL-C and triglyceride; Crossed curve (Blue), Adjusted for age, smoking status, duration of diabetes, HbA1c, Ln (ACR + 1),
gliclazide and rosiglitazone during follow up, years of enrolment (selected by the stepwise algorithm with P = .10 for inclusion and removal)
Figure 2 Hazard ratio of HDL-C for risk of CVD using restricted cubic spline Cox model analysis. Dotted curve (black), not adjusted for
other covariates except for LDL-C and triglyceride; Crossed curve (Blue), Adjusted for age, smoking status, duration of diabetes, HbA1c, Ln (ACR
+ 1), gliclazide and rosiglitazone during follow-up, years of enrolment (selected by the stepwise algorithm with P = .10 for inclusion and
removal)
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studies [15,24,25] have confirmed the benefits of statins on
CVD in primary and secondary prevention studies which
included diabetic and non-diabetic subjects. These benefi-
cial effects have recently been extended to patients with
LDL-C level less than the recommended treatment level of
2.6 mmol/L although these patients had high sensitivity C
reactive protein [26]. In the post-hoc analysis of the FIELD
study, treatment with fenofibrate reduced the risk of CVD
by 27% in a subgroup of type 2 diabetic patients with high
triglyceride and low HDL-C [27]. Echoing this finding, the
recently published ACCORD lipid study showed benefit of
fenofibrate in a subgroup of type 2 diabetic patients who
had both high triglyceride ≥ 2.30 mmol/L and low HDL-C
≤ 0.88 mmol/L [28]. We found use of statins was asso-
ciated with reduced risk of CVD in the whole group as
well as in those with high LDL-C, low HDL-C and meta-
bolic syndrome. The benefit of fibrates on CVD in the
whole group was rendered insignificant after adjusting for
confounders, probably due to the small sample size.
Recent genetic studies suggested possible inter-ethnic
differences in patterns of risk variants associated with
dyslipidaemia. For example, two single nucleotide poly-
morphisms of the KCNQ1 gene, a well-known type 2
diabetes gene, were associated with higher level of trigly-
cerides and lower levels of HDL-C in Chinese popula-
tion [29]. On the other hand, in Chinese type 2 diabetic
patients with concomitant coronary heart disease, the
PPARgC161 ༠ T genotype was associated with reduced
severity of atherosclerosis, in part medicated by
improved lipid metabolism of decreased the triglycerides
and apoB levels [30]. While these findings suggest that
triglyceride may be implicated in CVD in Chinese sub-
jects, after adjusting for cofounders, our overall results
concord with most studies regarding the importance of
LDL-C and statins in modifying CVD risk in Chinese.
Overcoming bias in pharmacoepidemiological study
Despite the growing epidemic of diabetes and expected
increase in CVD in Asia, there have not been any large
Figure 3 Hazard ratio of triglyceride for risk of CVD using restricted cubic spline Cox model analysis. Dotted curve (black), not adjusted
for other covariates except for LDL-C and HDL-C; Crossed curve (Blue), Adjusted for age, smoking status, duration of diabetes, HbA1c, Ln (ACR +
1), gliclazide and rosiglitazone during follow-up, years of enrolment (selected by the stepwise algorithm with P = .10 for inclusion and removal)
Table 2 Hazard ratios of lipid profile for risk of
cardiovascular disease in Chinese type 2 diabetic
patients
HR 95% CI P value
Model One†
LDL-C ≥ 3.0 mmol/L vs. <3.0 mmol/L 1.41 1.13 to1.75 .0024
HDL-C, mmol/L 0.61 0.45 to 0.84 .0080
Triglyceride, mmol/L 1.08 0.97 to 1.21 .1669
Model Two‡
LDL-C ≥ 3.0 mmol/L vs. <3.0 mmol/L 1.36 1.08 to 1.71 .0095
HDL-C, mmol/L 0.59 0.42 to 0.82 .0020
Triglyceride, mmol/L 1.02 0.88 to 1.17 .9614
†, Not adjusted for other covariates;
‡, Adjusted for age, smoking status, duration of diabetes, HbA1c, Ln (ACR +
1), use of statins, fibrates, gliclazide and rosiglitazone during follow-up, years
of enrolment (selected by the stepwise algorithm with P = .10 for entry and
stay).
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tins or fibrates in preventing CVD in Asian populations.
In the absence of such evidence, treatment recommen-
dations were largely empirical and derived from Wes-
tern guidelines. To our knowledge, our present analysis
is by far the largest prospective cohort of Asian type 2
diabetic patients with detailed documentation of risk
factors, drug usage and clinical outcomes. Our diabetes
registry provided useful information for guiding clinical
practice and for future large randomized clinical trials in
Chinese.
To circumvent potential bias inherent in an observa-
tional survey, we have used a new-user design and
excluded existing statins or fibrates users. Such design is
superior to traditional cohort studies as prevalent users
cause indication and adherence bias [31]. Besides, all
patients have undergone comprehensive assessment with
detailed documentation of other confounders which
were adjusted in our analysis. We further used propen-
sity score to adjust for bias due to prescribers’ prefer-
ence although we were unable to fully adjust for factors
such as volunteer bias which is often seen in patients
more compliant to treatment or follow up. After careful
analysis of the bias, we concluded that the drug use
definition was robust and did not introduce major bias
neither towards an increased nor decreased risk of the
endpoint [32].
Limitations
Our results need to be interpreted with the following
caveats. We only measured a single fasting plasma lipid
profile when plasma triglyceride level is known to have
marked day-to-day and intra-individual variability.
This may have attenuated the risk association between
triglyceride level and CVD outcomes. Our cohort was
predominantly clinic-based although given the heavily-
subsidized health care system in Hong Kong, our public
hospital clinics provide care to more than 90% patients
with chronic diseases such as diabetes [7]. Despite our
careful adjustment for potential confounders, a new-user
cohort design cannot replace a randomized controlled
trial which aims to remove bias due to unbalanced dis-
tribution of measured and unmeasured confounders.
In our survey, lipid levels were not systematically col-
lected during clinic visits after the initial enrolment. To
avoid bias due to unknown lipid levels during start of ther-
apy, we opted to use yes/no coding rather than time-
dependent use in our analysis. In these public hospital
Table 3 Hazard ratios of use of statin and fibrate for risk of cardiovascular disease in Chinese type 2 diabetic patients
Exposures HR 95%CI P value
In the entire cohort§†
Use of statins during follow-up 0.66 0.50 to 0.88 .0038
Use of fibrates during follow-up 0.61 0.37 to 1.03 .0640
In the sub-cohort with LDL-C < 3.0 mmol/L¶, §
Use of statins during follow-up 1.10 0.56 to 2.16 .7798
Use of fibrates during follow-up 0.34 0.12 to 1.00 .0495
In the sub-cohort with LDL-C ≥ 3.0 mmol/L¶, §
Use of statins during follow-up 0.60 0.44 to 0.82 .0012
Use of fibrates during follow-up 0.65 0.35 to 1.19 .1590
In the sub-cohort with HDL-C < 1.0 mmol/L in male or 1.3 mmol/L in female ζ,§
Use of statins during follow-up 0.49 0.28 to 0.88 .0162
Use of fibrates during follow-up 0.37 0.13 to 1.09 .0703
In the sub-cohort with HDL-C ≥1.0 mmol/L in male or ≥ 1.3 mmol/L in female ζ,§
Use of statins during follow-up 0.73 0.53 to 1.02 .0662
Use of fibrates during follow-up 0.74 0.41 to 1.35 .3303
In the sub-cohort with metabolic syndrome at baseline ‡,§
Use of statins during follow-up 0.58 0.42 to 0.80 .0010
Use of fibrates during follow-up 0.60 0.35 to 1.05 .0713
In the sub-cohort without metabolic syndrome at baseline ‡,§
Use of statins during follow-up 0.77 0.42 to 1.44 .4201
Use of fibrates during follow-up 0.57 0.12 to 2.73 .4903
†Adjusted for LDL-C (≥ 3.0 mmol/L vs. < 3.0 mmol/L), HDL-C, triglyceride, age, smoking status, duration of diabetes, HbA1c, Ln (ACR + 1), gliclazide and
rosiglitazone during follow-up, years of enrolment (selected by the stepwise algorithm with P = .10 for entry and stay);
Adjusted for the variables listed in ‡, except for LDL-C;
ζ, Adjusted for the variables listed in ‡, except for HDL-C;
§, Cox models stratified on deciles of probability of initiation of statin therapy during follow-up and on deciles of probability of initiation of fibrate therapy
during follow-up.
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and simvastatin were available with atorvastatin (10-20 mg
daily) and simvastatin (10-40 mg daily) being the two
most popular statins. For fibrates, bezafibrate and gemfi-
brozil were both available with gemfibrozil being the more
popular choice. However, with the relatively small sample
size of patients on statins and fibrates, we were not able to
examine the effects of individual drug on CVD. We also
did not document the drug compliance of the patients or
check whether other private drugs were used. Although
non compliance or occasional drug omission is not
uncommon in patients on long term medications, this
would tend to attenuate effect size and level of signifi-
cance. Besides, surveys by our other colleagues have
reported more than 90% compliance amongst patients tak-
ing lipid regulating drugs [33,34].
Conclusions
In conclusion, in a relatively large prospective cohort of
Chinese type 2 diabetic patients without past history of
CVD, both LDL-C (≧ 3.0 mmol/L) and HDL-C level but
not the triglyceride level predicted incident CVD. Use of
statins was associated with reduced CVD risk in patients
with high LDL-C level, low HDL-C level or metabolic
syndrome while fibrates use was associated with reduced
CVD in patients with low LDL-C Given the narrow risk-
benefit ratio of intensive blood glucose lowering in type
2 diabetic patients especially those with long disease
duration who often have silent ischemic disease [35],
patients and health-care professionals must be aware of
the importance of attaining recommended lipid goals to
reduce CVD risks.
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